Business
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteersOV329 showed favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses, supporting the planned advancement of Phase 2 and proof-of-concept studiesAnnounced development expansion of OV329 into additional pediatric indications of tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), c
About this update from Ovid Therapeutics Inc.
[{"type":"image","alt":"Ovid Therapeutics Inc.","displaySize":"","headline":null,"caption":"Ovid Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0SW3Gga9_s2CrsX4gElIDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OQ--/https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802","width":300,"height":142},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/0SW3Gga9_s2CrsX4gElIDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OQ--/https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802","width":300,"height":142}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"OV329 showed favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses, supporting the planned advancement of Phase 2 and proof-of-concept studies","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced development expansion of OV329 into additional pediatric indications of tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), conditions for which GABA-aminotransferase (GABA-AT) inhibition is a validated mechanism","length":239,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened balance sheet, raising $60.0 million of gross proceeds in March 2026 PIPE financing with participation from leading healthcare investors","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Received $53.9 million in gross proceeds upon full exercise of Series A warrants in connection with October 2025 PIPE financing","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities were $165.6 million as of March 31, 2026, which does not include $27.3 million in proceeds received in April 2026 from exercise of Series A warrants","length":202,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1065,"olType":false},{"type":"text","content":"NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ...